EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

[ 177 Lu]Lu‐PSMA‐617 Plus Short‐Course Priming With Enzalutamide in Metastatic Castration‐Resistant Prostate Cancer: A Single‐Arm Phase 2 Trial (Lu‐PRIME)

Piyush Aggarwal iD, Ashwani Sood iD, Swayamjeet Satapathy iD, Shikha Goyal iD, Komalpreet Kaur, Gaurav Prakash iD, Kannan Periasamy iD, Bhagwant Rai Mittal iD

The Prostate · 2026-12 · 86 (16) · 1630-1636

DOI: 10.1002/pros.70253 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift The Prostate, online erschienen am 13.09.2026. Verfasst von Piyush Aggarwal und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Benzamides, Dipeptides, Heterocyclic Compounds, 1-Ring. Die Arbeit nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background [ 177 Lu]Lu‐PSMA‐617 has been an approved treatment modality for metastatic castration‐resistant prostate cancer (mCRPC). Recent studies have shown PSMA upregulation following enzalutamide, which may enhance the outcomes with [ 177 Lu]Lu‐PSMA‐617. This study aims to evaluate the efficacy and safety of short‐course enzalutamide priming with [ 177 Lu]Lu‐PSMA‐617 in mCRPC patients.

Methods

This investigator‐initiated, single‐arm phase 2 trial recruited men with mCRPC, having progressed on ≥one line of taxane and androgen‐receptor pathway inhibitors (ARPIs), and fit for [ 177 Lu]Lu‐PSMA‐617. Enzalutamide (160 mg/day) was administered orally for 7 days before and after [ 177 Lu]Lu‐PSMA‐617 (7.4 GBq/cycle, up to 6 cycles, at 6–8 week intervals). The primary end‐point was proportion of patients achieving ≥ 50% decline in prostate‐specific antigen (PSA50‐response rate, PSA50‐RR). A sample size of 20 patients was calculated using Simon's two‐stage design with at least 12/20 PSA50‐responses required for rejection of null hypothesis. Secondary end‐points included objective radiographic response rate (ORR), PSA progression‐free survival (PSA‐PFS), radiographic PFS (rPFS), overall survival (OS), and adverse events (AEs).

Results

Between May 2023 and January 2025, 20 mCRPC patients (median age 67 years) were enrolled. The PSA50‐RR was 40% (8/20, 95% CI: 19–64), thus the null hypothesis was not rejected. The ORR was 25% (5/20, 95% CI: 10–49). Over a median follow‐up of 24 months, median PSA‐PFS, rPFS, and OS were 4.0 months (95% CI: 3.0–7.5), 4.0 months (95% CI: 4.0–7.5), and 12.6 months (95% CI: 6.2–17.0), respectively. Grade 3 AEs were observed in four patients (20%, 95% CI: 6–44).

Conclusion

The addition of short‐course enzalutamide to [ 177 Lu]Lu‐PSMA‐617 did not meaningfully improve treatment outcomes of taxane and ARPI‐exposed mCRPC patients in this trial. Trial Registration Clinical Trials Registry‐India, CTRI/2023/05/053301. Registered 31 May 2023.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBenzamidesDipeptidesHeterocyclic Compounds, 1-RingNitrilesPhenylthiohydantoinProstatic Neoplasms, Castration-ResistantAgedAged, 80 and overHumansMaleMiddle AgedLutetiumProstate-Specific AntigenRadioisotopes

Stichwörter der Autor:innen

[177Lu]Lu‐PSMA‐617androgencastration‐resistantenzalutamideprostatic neoplasmsreceptors

Substanzen

BenzamidesDipeptidesenzalutamideHeterocyclic Compounds, 1-RingLutetiumLutetium-177NitrilesPhenylthiohydantoinProstate-Specific AntigenPSMA-617

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
  • Department of Nuclear Medicine, Sri Aurobindo Medical College and P. G. Institute, SAU, Indore, India.
  • Department of Nuclear Medicine, Rohilkhand Medical College and Hospital, Bareilly, India.
  • Department of Nuclear Medicine, Mahamana Pandit Madan Mohan Malaviya Cancer Centre & Homi Bhabha Cancer Hospital, Tata Memorial Centre, Varanasi, India.
  • Department of Radiotherapy and Oncology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
  • Department of Clinical Hematology and Medical Oncology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.

ORCID-Profile: Piyush Aggarwal, Ashwani Sood, Swayamjeet Satapathy, Shikha Goyal, Gaurav Prakash, Kannan Periasamy, Bhagwant Rai Mittal

Zitieren

APA

Aggarwal, P., Sood, A., Satapathy, S., Goyal, S., Kaur, K., Prakash, G., Periasamy, K., & Mittal, B. R. (2026). [ 177 Lu]Lu‐PSMA‐617 Plus Short‐Course Priming With Enzalutamide in Metastatic Castration‐Resistant Prostate Cancer: A Single‐Arm Phase 2 Trial (Lu‐PRIME). The Prostate, 86(16), 1630-1636. https://doi.org/10.1002/pros.70253

Vancouver

Aggarwal P, Sood A, Satapathy S, Goyal S, Kaur K, Prakash G, et al. [ 177 Lu]Lu‐PSMA‐617 Plus Short‐Course Priming With Enzalutamide in Metastatic Castration‐Resistant Prostate Cancer: A Single‐Arm Phase 2 Trial (Lu‐PRIME). The Prostate. 2026;86(16):1630-1636. doi:10.1002/pros.70253

BibTeX
@article{Aggarwal2026,
  author = {Aggarwal, Piyush and Sood, Ashwani and Satapathy, Swayamjeet and Goyal, Shikha and Kaur, Komalpreet and Prakash, Gaurav and Periasamy, Kannan and Mittal, Bhagwant Rai},
  title = {[ 177 Lu]Lu‐PSMA‐617 Plus Short‐Course Priming With Enzalutamide in Metastatic Castration‐Resistant Prostate Cancer: A Single‐Arm Phase 2 Trial (Lu‐PRIME)},
  journal = {The Prostate},
  year = {2026},
  volume = {86},
  number = {16},
  pages = {1630--1636},
  doi = {10.1002/pros.70253}
}
Kostenlos starten →